Behcet's Disease Market Trends

Growth Drivers

• Technological Development in the Healthcare Sector: The treatment of Behcet’s disease is assisted by the specific symptoms that are clearly visible in each individual. The widespread increase in the disease has led to growth in demand for chronic disease management characterized by inflammation of various organs. For reducing the inflammation two specific therapies were used: supportive and symptomatic. Treatment choices are determined by the patient's age, sex, and disease severity. For instance, a study published in 2023 states that using the Egyptian College of Rheumatology (ECR)-BD cohort various machine learning models were developed for detection of vision-threatening behcet’s disease.
• Increasing Expenditure on Healthcare Sector by the Government: Government programs and funding for research work on rare disorders can have a big impact on the behcet's disease market. The development of drugs and patient access to treatment can be improved by with grants & funding. According to the American Behcet’s Disease Association, a person can claim social security disability benefits if the person is suffering from behcet’s disease.
• FDA Approval for Medications: With the increasing number of cases of Behcet’s disease, researchers have discovered various drugs have the potential to reduce inflammation. For instance, a report published by the American Behcet’s Disease Association in 2019 states that the US Food and Drug Administration (FDA) has approved the use of apremilast drug (Otezla, Celgene) 30 mg twice a day for the treatment of oral ulcers in adults associated with Behçet's disease. It’s an oral elective phosphodiesterase 4 (PDE4) inhibitor used for treating oral ulcers associated with Behcet's Disease. Apremilast was approved as a 30 mg twice-daily therapy which can be prescribed to an adult. Multiple systems can be affected by the presence of this disease, but it's often characterized by reoccurring of oral ulcers along with lesions in other organ systems.

Challenges

• Difficulty in Diagnosis Hinders Market Expansion: There’s no specific diagnostic technique for Behcet’s disease. A physician's experience is the only consideration in diagnosing the condition. Multiple studies show that Behcet's disease patients find it difficult to lead normal lives due to the degenerative nature of the disease. The inability to precisely diagnose the indication is anticipated to seriously hinder the growth of the worldwide Behcet’s syndrome treatment market during the forecast year.
• Lack of knowledge among the population, medical practitioners and specialists lead to a delayed or inaccurate diagnosis.
• People not responding well to specific medications & therapies available for reducing inflammation.